Reduced natural cytotoxic cell activity in patients receiving cisplatin-based chemotherapy and in mice treated with cisplatin.

od Powell, C B, Mutch, D G, Kao, M S, Collins, J L
Izdano 1990

Pelvic exenteration in gynecologic oncology: A single institution study over 20 years

od Benn, T., Brooks, R.A., Zhang, Q., Powell, M.A., Thaker, P.H., Mutch, D.G., Zighelboim, I
Izdano u Gynecol Oncol (2011)

Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer

od Johns, E.A., Stanley, J.A., Toboni, M.D., Schwarz, J.K., Zhang, F., Hagemann, A.R., Fuh, K.C., Thaker, P.H., McCourt, C.K., Mutch, D.G., Powell, M.A., Khabele, D., Kuroki, L.M.
Izdano u Gynecol Oncol Rep (2021)

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study

od Hamilton, C. A., Miller, A., Casablanca, Y., Horowitz, N. S., Rungruang, B., Krivak, T. C., Richard, S. D., Rodriguez, N., Birrer, M.J., Backes, F.J., Geller, M.A., Quinn, M., Goodheart, M.J., Mutch, D.G., Kavanagh, J.J., Maxwell, G. L., Bookman, M. A.
Izdano u Gynecol Oncol (2017)

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

od Thaker, P. H., Salani, R., Brady, W. E., Lankes, H. A., Cohn, D. E., Mutch, D. G., Mannel, R. S., Bell-McGuinn, K. M., Di Silvestro, P. A., Jelovac, D., Carter, J. S., Duan, W., Resnick, K. E., Dizon, D. S., Aghajanian, C., Fracasso, P. M.
Izdano u Ann Oncol (2017)

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study

od Felix, A.S., Brasky, T.M., Cohn, D.E., Mutch, D.G., Creasman, W.T., Thaker, P.H., Walker, J.L., Moore, R.G., Lele, S.B., Guntupalli, S.R., Downs, L.S., Nagel, Ci, Boggess, J.F., Pearl, M.L., Ioffe, O.B., Deng, W., Miller, D.S., Brinton, L.A.
Izdano u Int J Cancer (2017)